TEL AVIV, Israel, April 02, 2026 (GLOBE NEWSWIRE) — Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a frontrunner within the improvement of oral peptides, as we speak introduced that it has entered right into a securities buy settlement for a non-public placement (the “Private Placement”) led by funds affiliated with BVF Companions L.P. (“BVF”).
The Non-public Placement is anticipated to shut on or about April 2, 2026, topic to customary closing circumstances. Pursuant to the Non-public Placement, the Firm agreed to situation and promote an mixture of seven,827,789 items (the “Units”) at a purchase order value of $1.2775 per Unit. Every Unit consists of (i) one extraordinary share of Entera (or, in lieu thereof, one pre-funded warrant) and (ii) one five-year warrant to buy one and a half extraordinary shares at an train value of $1.24 per share, representing a 11.7% premium to the Firm’s closing value on March 31, 2026.
Gross proceeds to the Firm from the Non-public Placement are anticipated to be roughly $10.0 million, earlier than deducting providing bills, topic to satisfaction of customary closing circumstances. If all warrants issued within the Non-public Placement are exercised for money, the Firm may obtain further proceeds of roughly $14.5 million, leading to complete potential proceeds of roughly $24.5 million.
The warrants to be issued within the Non-public Placement will grow to be exercisable six months following the time limit, and can expire 5 years following the date of issuance. The warrants might be exercisable just for money, besides in sure circumstances. The pre-funded warrants to be issued within the Non-public Placement can have an train value of NIS 0.0000769 per share, might be instantly exercisable upon issuance and won’t expire.
The Firm intends to make use of the web proceeds from the Non-public Placement along with present money and money equivalents to help actions associated to initiation of the section 3 registrational examine of EB613 in postmenopausal ladies with osteoporosis and for normal working capital and company functions.
More Read
The securities described above are being supplied in a non-public placement pursuant to the exemption from registration below Part 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and haven’t been registered below the Securities Act or relevant state securities legal guidelines. Accordingly, the securities might not be supplied or offered in the USA absent registration or an relevant exemption from such registration necessities.
This press launch shall not represent a suggestion to promote or a solicitation of a suggestion to purchase any securities, nor shall there be any sale of those securities in any jurisdiction during which such supply, solicitation or sale could be illegal.
About Entera BioEntera is a scientific stage firm targeted on growing oral peptide and protein substitute therapies for important unmet medical wants the place an oral pill kind holds the potential to rework the usual of care. The Firm leverages a disruptive and proprietary expertise platform (N-Tab®) and its pipeline of first-in-class oral peptide packages. The Firm’s most superior product candidate, EB613 (oral PTH(1-34)), is being developed as the primary oral, osteoanabolic (bone constructing) once-daily pill for osteoporosis. A placebo-controlled, dose-ranging Part 2 examine of EB613 tablets (n= 161) met main (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera can be growing the primary oral Lengthy Performing PTH(1-34) pill as a substitute remedy for sufferers with hypoparathyroidism (EB612), the primary oral oxyntomodulin, a twin focused GLP1/glucagon peptide pill for the remedy of weight problems and metabolic syndromes; and the primary oral GLP-2 pill as an injection-free different for sufferers affected by uncommon malabsorption circumstances resembling quick bowel syndrome in collaboration with OPKO Well being, Inc. For extra info on Entera Bio, go to www.enterabio.com or comply with us on LinkedIn, Twitter, and Fb.
Cautionary Assertion Concerning Ahead Trying StatementsVarious statements on this press launch are “forward-looking statements” throughout the which means of the Non-public Securities Litigation Reform Act of 1995. All statements (aside from statements of historic info) on this press launch concerning our prospects, plans, monetary place, enterprise technique, scientific improvement actions, collaboration preparations and anticipated monetary and operational outcomes are forward-looking statements. Phrases resembling, however not restricted to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the unfavourable of those phrases and comparable expressions or phrases, determine forward-looking statements. Ahead-looking statements are primarily based upon present expectations that contain dangers, modifications in circumstances, assumptions and uncertainties. Ahead-looking statements shouldn’t be learn as a assure of future efficiency or outcomes and might not be correct indications of when such efficiency or outcomes might be achieved. Necessary elements that might trigger precise outcomes to vary materially from these mirrored in Entera’s forward-looking statements embrace, amongst others: modifications within the interpretation of scientific information; outcomes of our scientific trials; the FDA’s interpretation and evaluation of our outcomes from and evaluation of our scientific trials; sudden modifications in our ongoing and deliberate preclinical improvement and scientific trials, the timing of and our capability to make regulatory filings and procure and keep regulatory approvals for our product candidates; the potential disruption and delay of producing provide chains; lack of out there workforce sources, both by Entera or its collaboration and laboratory companions; impacts to analysis and improvement or scientific actions that Entera could also be contractually obligated to offer; total regulatory timelines; the dimensions and development of the potential markets for our product candidates; the scope, progress and prices of growing Entera’s product candidates; Entera’s reliance on third events to conduct its scientific trials; Entera’s capability to determine and keep improvement and commercialization collaborations; Entera’s operation as a improvement stage firm with restricted working historical past; Entera’s aggressive place with respect to different merchandise in the marketplace or in improvement for the remedy of osteoporosis, hypoparathyroidism, quick bowel syndrome, weight problems, metabolic circumstances and different illness classes it pursues; Entera’s capability to proceed as a going concern absent entry to sources of liquidity; Entera’s capability to acquire and keep regulatory approval for any of its product candidates; Entera’s capability to adjust to Nasdaq’s minimal itemizing requirements and different issues associated to compliance with the necessities of being a public firm in the USA; Entera’s mental property place and its capability to guard its mental property; and different elements which are described within the “Cautionary Statement Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s most up-to-date Annual Report on Type 10-Ok filed with the SEC, in addition to Entera’s subsequently filed Quarterly Reviews on Type 10-Q and Present Reviews on Type 8-Ok. There might be no assurance that the precise outcomes or developments anticipated by Entera might be realized or, even when considerably realized, that they’ll have the anticipated penalties to, or results on, Entera. Due to this fact, no assurance might be on condition that the outcomes acknowledged or implied in such forward-looking statements and estimates might be achieved. Entera cautions traders to not depend on the forward-looking statements Entera makes on this press launch. The knowledge on this press launch is offered solely as of the date of this press launch, and Entera undertakes no obligation to replace or revise publicly any forward-looking statements, whether or not because of new info, future occasions or in any other case, besides to the extent required by legislation.
